Diplomat Pharmacy Stock Price, News & Analysis (NYSE:DPLO)

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

Diplomat Pharmacy Inc (NYSE:DPLO) issued its quarterly earnings results on Friday, August, 9th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.23 billion. Diplomat Pharmacy had a negative return on equity of 4.01% and a negative net margin of 8.93%. The business's revenue for the quarter was down 9.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.05) earnings per share. View Diplomat Pharmacy's Earnings History.

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Diplomat Pharmacy.

Diplomat Pharmacy issued an update on its FY19 earnings guidance on Friday, August, 9th. The company provided EPS guidance of ($2.69-2.55) for the period, compared to the Thomson Reuters consensus estimate of ($0.54). The company issued revenue guidance of $4.7-5.0 billion, compared to the consensus revenue estimate of $4.91 billion.

14 equities research analysts have issued 12 month target prices for Diplomat Pharmacy's shares. Their predictions range from $4.00 to $30.00. On average, they anticipate Diplomat Pharmacy's stock price to reach $9.65 in the next twelve months. This suggests a possible upside of 100.7% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 3 sell ratings, 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

Media headlines about DPLO stock have trended very negative on Thursday, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Diplomat Pharmacy earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Diplomat Pharmacy.

Diplomat Pharmacy saw a drop in short interest during the month of September. As of September 15th, there was short interest totalling 7,680,000 shares, a drop of 7.6% from the August 15th total of 8,310,000 shares. Based on an average daily volume of 790,800 shares, the short-interest ratio is presently 9.7 days. Approximately 13.3% of the shares of the stock are sold short. View Diplomat Pharmacy's Current Options Chain.

Some companies that are related to Diplomat Pharmacy include Covetrus (CVET), Rite Aid (RAD), 111 (YI), Petmed Express (PETS), China Jo-Jo Drugstores (CJJD), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Diplomat Pharmacy investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), General Electric (GE), CVS Health (CVS), Cannabis Sativa (CBDS), Horizon Therapeutics (HZNP), Servicesource International (SREV), Ford Motor (F), Activision Blizzard (ATVI) and Cara Therapeutics (CARA).

Diplomat Pharmacy's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.40%) and State of Alaska Department of Revenue (0.06%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Joel Saban, Kenneth O Klepper, Philip R Hagerman, Regina M Benjamin and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

DPLO stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Atul Kavthekar, Kenneth O Klepper and Regina M Benjamin. View Insider Buying and Selling for Diplomat Pharmacy.

DPLO stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DPLO stock can currently be purchased for approximately $4.81.

Diplomat Pharmacy has a market capitalization of $364.74 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.View Additional Information About Diplomat Pharmacy.

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/.

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]